ADHD, schizophrenia and methylphenidate
The use of methylphenidate (MPH) to treat attention deficit hyperactivity disorder (ADHD) in patients with comorbid psychosis is controversial, with much evidence to suggest that stimulants can increase psychosis levels in 50–70% of patients with schizophrenia. This is not surprising when one considers the mode of action of stimulant drugs and the dopamine hypothesis of schizophrenia.
ADHD in practice 2010; 2(2): 8–10
To continue reading this article, please sign in or register.